Zobrazeno 1 - 10 of 14 pro vyhledávání: '"R. V. LaRocca"'
1
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
Autor: McClellan M. Walther, R V LaRocca, Michael R. Cooper, M M Uhrich, P. L. Choyke, Seth M. Steinberg, Cy A. Stein, Nancy A. Dawson, G Weiss, Charles E. Myers
Publikováno v: Journal of Clinical Oncology. 10:881-889
PURPOSE Suramin is known to inhibit the growth of malignant prostate carcinoma cells in vitro. This led us to evaluate the effectiveness of suramin in the treatment of 38 patients with prostate carcinoma refractory to hormone therapy. PATIENTS AND ME
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4500a5c8b35f919ee1abe8cb3eb960bf
https://doi.org/10.1200/jco.1992.10.6.881
Zobrazit plný text záznamu
2
A phase II clinical trial utilizing maximum medical and surgical cytoredutive treatments for patients with metastatic colorectal cancer to the liver
Autor: George H. Goldsmith, Shawn D. Glisson, R. V. Larocca, J. B. Hargis, A. Cervera, D. D. Repishti, J. E. Sunderland, B. Cornell
Publikováno v: Journal of Clinical Oncology. 27:e15130-e15130
e15130 Background: The median overall survival (‘OS‘) for patients with mCRC treated with chemotherapy is about 20.4 months. Combination chemotherapy with surgical cytoreduction for patients with liver metastases are evaluated in a phase II clini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db4555cdef9bbf6d4e0dbd039f9602bb
https://doi.org/10.1200/jco.2009.27.15_suppl.e15130
Zobrazit plný text záznamu
3
Characteristics of cell lines established from human gastric carcinoma
Autor: J G, Park, H, Frucht, R V, LaRocca, D P, Bliss, Y, Kurita, T R, Chen, J G, Henslee, J B, Trepel, R T, Jensen, B E, Johnson
Publikováno v: Cancer research. 50(9)
We report the establishment and characterization of four continuous cell lines derived from human primary and metastatic gastric carcinomas, and we compare their properties with a panel of colorectal carcinoma cell lines previously established and re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::094bb9630a52b46108acc1bddef89d3c
https://pubmed.ncbi.nlm.nih.gov/2158397
Zobrazit plný text záznamu
4
Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC)
Autor: Mark A. Socinski, R. E. Bordoni, D. S. Bradford, R. V. LaRocca, Thomas A. Hensing
Publikováno v: Journal of Clinical Oncology. 25:18005-18005
18005 Background: Cetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) on both normal and tumor cells, has been investigated in advanced NSCLC as a single agent and in combination with chemotherapy. At the time
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de30ad3a5bcfb302163fe9bb68939967
https://doi.org/10.1200/jco.2007.25.18_suppl.18005
Zobrazit plný text záznamu
5
A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)
Autor: R. Vassilopoulou-Sellin, B. F. Cole, A. T. Fojo, D. I. Quinn, W. K. Oh, Marc S. Ernstoff, Vincent A. Memoli, P. A. Simmons, C. P. Tretter, V. Samnotra, R. V. LaRocca
Publikováno v: Journal of Clinical Oncology. 25:15527-15527
15527 Background: ACC is a rare malignancy with a very poor prognosis. Surgery is the only potential curative option. Gefitinib is an oral EGFR inhibitor that may have activity in solid tumors that express EGFR. ACC over expresses EGFR in a high prop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9aa935c4c4f3d5f3505bf0e21804078
https://doi.org/10.1200/jco.2007.25.18_suppl.15527
Zobrazit plný text záznamu
7
Phase II study of cyclophosphamide, etoposide and estramustine in patients with androgen independent prostate cancer
Autor: M. A. Choudry, F. J. Hendler, R. V. Larocca, L. Bhupalam, A. C. Mehta, Goetz H. Kloecker, Vivek R. Sharma, C. Crump, Damian A. Laber, Donald M. Miller
Publikováno v: Journal of Clinical Oncology. 23:4757-4757
4708 Background: Novel and effective therapies for patients with AIPC are needed. Oral therapy offers the tremendous advantage of independence and avoids all the catheter-related complications. Cyclophosphamide, etoposide and estramustine have shown
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::973d8dd9221457a590117a62fbde9e1b
https://doi.org/10.1200/jco.2005.23.16_suppl.4757
Zobrazit plný text záznamu
9
Patterns of proto-oncogene expression in human glioma cell lines
Autor: Bengt Westermark, R. V. LaRocca, Mark L. Rosenblum, M. A. Israel
Publikováno v: Journal of Neuroscience Research. 24:97-106
Previously reported studies have suggested that variations in the pattern of proto-oncogene expression within a specific tumor type may denote an underlying difference in the biology and clinical behavior of those tumors. To more sensitively characte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aa70973c858e58128e6e8028f7e4855
https://doi.org/10.1002/jnr.490240114
Zobrazit plný text záznamu
10
Suramin: an anticancer drug with a unique mechanism of action
Autor: R Thomas, Nanette McAtee, Charles E. Myers, R V LaRocca, Cy A. Stein
Publikováno v: Journal of Clinical Oncology. 7:499-508
We administered suramin, an anti-parasitic drug and reverse transcriptase inhibitor, to 15 patients with metastatic cancer. This compound is known to inhibit the binding of growth factors (eg, epidermal growth factor [EGF], platelet-derived growth fa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354717c2e7ece44a3b1127181e640925
https://doi.org/10.1200/jco.1989.7.4.499
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje